NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors

#1676

Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).

Aim(s): EORTC questionnaires C30 and GINET21 were used to determine the impact of treatment on health-related quality of life (HRQoL).

Materials and methods: Patients completed the two QoL questionnaires at baseline and every 12 weeks until disease progression. Individual changes from baseline scores were assessed. Deteriorations/improvements were considered clinically significant when ≥10 points.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,